Literature DB >> 19107076

[Long-chain 3-hydroxyacyl CoA dehydrogenase deficiency and choroidal neovascularization].

D Stopek1, E Gitteau Lala, F Labarthe, M L Le Lez, S Majzoub, P Castelnau, P J Pisella.   

Abstract

We report the case of a 9-year-old girl with a long-chain 3-hydroxyacyl CoA dehydrogenase (LCHAD) deficiency. This enzyme participates in mitochondrial fatty acid B-oxidation. Genetic fatty acid oxidation defects induce cellular energetic deficiency, and thus early life-threatening manifestations. An appropriate diet prevents these severe disorders. Nevertheless, LCHAD deficiency is the only B-oxidation enzymatic disorder that induces a chorioretinopathy, predominating at the posterior pole. We describe the first case of bilateral macular choroidal neovascularization. One eye presented a fibrovascular lesion. The other eye presented an active neovascularization stabilized by two dynamic phototherapies. The specificity of choroidal degeneration related to LCHAD deficiency remains unknown. Reviewing of literature and biochemical mechanisms suggests that fatty acid oxidative stress rather than a mitochondrial energetic defect is involved. For practical purposes, this report emphasizes the importance of ophthalmological follow-up of these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19107076     DOI: 10.1016/s0181-5512(08)74746-6

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  2 in total

1.  [Ocular signs of a mitochondrial trifunctional protein defect. A long-term follow-up].

Authors:  T Ach; G Kolling; K Rohrschneider; C Richter; D Haas; A Schmidt-Bacher
Journal:  Ophthalmologe       Date:  2012-03       Impact factor: 1.059

2.  Characterization of Chorioretinopathy Associated with Mitochondrial Trifunctional Protein Disorders: Long-Term Follow-up of 21 Cases.

Authors:  Erin A Boese; Nieraj Jain; Yali Jia; Catie L Schlechter; Cary O Harding; Simon S Gao; Rachel C Patel; David Huang; Richard G Weleber; Melanie B Gillingham; Mark E Pennesi
Journal:  Ophthalmology       Date:  2016-08-02       Impact factor: 12.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.